Table 2.
Odds ratios for endometrial cancer associated with gene variants
| Gene/SNP (aliases) | Genotype | Cases n (%) |
Controls n (%) |
ORa (95% CI) | Ptrend | ORb (95%CI) | Ptrend |
|---|---|---|---|---|---|---|---|
|
CYP19 rs4775936 (5'Flank, G to A in exon 1.6) |
GG | 117 (30%) | 238 (34%) | 1.0 | 1.00 | ||
| GA | 185 (47%) | 357 (50%) | 1.03 (0.78, 1.37) | 1.08 (0.80, 1.46) | |||
| AA | 89 (23%) | 114 (16%) | 1.51 (1.05, 2.16) | 1.55 (1.06, 2.27) | |||
| Per allele | 1.20 (1.01, 1.44) | 0.04 | 1.22 (1.01, 1.47) | 0.04 | |||
|
CYP19 rs10046 (3'UTR, C to T in intron 4) |
CC | 96 (25%) | 206 (29%) | 1.0 | 1.00 | ||
| CT | 200 (51%) | 365 (52%) | 1.15 (0.85, 1.55) | 1.19 (0.86, 1.64) | |||
| TT | 95 (24%) | 138 (19%) | 1.42 (0.99, 2.05) | 1.44 (0.98, 2.12) | |||
| Per allele | 1.19 (0.99, 1.43) | 0.06 | 1.20 (0.99, 1.45) | 0.06 | |||
|
CYP1B1 rs1800440 (A4390G, Asn453Ser) |
AA | 283 (73%) | 496 (70%) | 1.00 | 1.00 | ||
| AG/GG | 106 (27%) | 213 (30%) | 0.88 (0.66, 1.15) | 0.34 | 0.91 (0.68, 1.21) | 0.51 | |
| CYP1B1 rs1056836 (*3, C4326G, Leu432Val) |
CC | 126 (32%) | 221 (31%) | 1.0 | 1.00 | ||
| CG | 189 (48%) | 352 (50%) | 0.96 (0.72, 1.28) | 0.99 (0.73, 1.34) | |||
| GG | 76 (20%) | 131 (19%) | 1.11 (0.77, 1.60) | 1.08 (0.73, 1.61) | |||
| Per allele | 1.04 (0.87, 1.25) | 0.66 | 1.03 (0.85, 1.25) | 0.75 | |||
|
UGT1A1 rs8175347 (*28 and *33, ≥7 TA repeats in TATA box of the promoter) |
6/6 | 171 (45%) | 311 (45%) | 1.0 | 1.00 | ||
| 6/7 | 163 (43%) | 296 (43% | 0.96 (0.74, 1.26) | 0.91 (0.68, 1.22) | |||
| 7/7 | 46 (12%) | 82 (12%) | 1.01 (0.65, 1.57) | 0.95 (0.59, 1.53) | |||
| Per allele | 0.99 (0.81, 1.21) | 0.92 | 0.95 (0.77, 1.18) | 0.65 | |||
|
SHBG rs6259 (G5790A) |
GG | 307 (81%) | 548 (81%) | 1.0 | 1.00 | ||
| GA/AA | 73 (19%) | 131 (19%) | 1.03 (0.75, 1.42) | 0.86 | 1.02 (0.72, 1.45) | 0.90 | |
|
PGR rs1042838 (V660L) |
GG | 281 (72%) | 540 (76%) | 1.00 | 1.00 | ||
| GT | 96 (24%) | 147 (21%) | 1.21 (0.90, 1.62) | 1.28 (0.93, 1.76) | |||
| TT | 14 (4%) | 18 (3%) | 1.38 (0.67, 2.86) | 1.42 (0.65, 3.09) | |||
| Per allele | 1.19 (0.94, 1.52) | 0.14 | 1.25 (0.96, 1.61) | 0.09 | |||
|
ESR1 rs2234693 (T397C, Pvull in intron 1, IVS1-401) |
TT | 116 (30%) | 194 (27%) | 1.0 | 1.00 | ||
| TC | 184 (47%) | 369 (52%) | 0.86 (0.64, 1.16) | 0.89 (0.65, 1.23) | |||
| CC | 91 (23%) | 146 (21%) | 1.06 (0.74, 1.51) | 1.12 (0.77, 1.64) | |||
| Per allele | 1.02 (0.85, 1.22) | 0.84 | 1.05 (0.87, 1.27) | 0.61 |
a
Adjusted for race (Caucasian, African-American, Hispanic, Other/Unknown) and controlled (through matching) for age, menopausal status at blood donation and biospecimen storage duration.
b
Adjusted, age at menarche (<12, 12, 13, >13, missing), parity (ever, never, missing), oral contraceptive use (never, ever, missing), hormone replacement therapy use (never, ever, missing), and BMI (<25, 25–30, >30, missing), in addition to factors in 1.